Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Cybin Inc. - Common Stock (NQ:HELP)

5.515 +0.295 (+5.65%)
Streaming Delayed Price Updated: 1:09 PM EDT, May 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Cybin Inc. - Common Stock

InvestorNewsBreaks – Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) Issues Correction To TARA Mind Partnership Announcement
Via Investor Brand Network
News headline image
CORRECTION: Helus Pharma Partners with TARA Mind to Advance Veteran Mental Health
From Helus Pharma
Via GlobeNewswire
News headline image
Helus Pharma to Participate at the 29th Annual Milken Institute Global Conference
From Helus Pharma
Via GlobeNewswire
MissionIRNewsBreaks – Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) Partners With TARA Mind to Support Phase 3 Trial Recruitment in Veterans
Via Investor Brand Network
News headline image
Helus Pharma Partners with TARA Mind to Advance Veteran Mental Health
From Helus Pharma
Via GlobeNewswire
BioMedNewsBreaks – Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) Adds Robert Langer, Stephen Brannan To Scientific Advisory Board
Via Investor Brand Network
News headline image
Helus Pharma Strengthens Scientific Advisory Board with Addition of Dr. Robert Langer and Dr. Stephen Brannan
From Helus Pharma
Via GlobeNewswire
PsychedelicNewsBreaks –  Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) Supports Executive Order Advancing Psychedelic Therapies
Via Investor Brand Network
InvestorNewsBreaks – Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) CEO Steps Down, Eric So Named Interim Chief Executive Office
Via Investor Brand Network
News headline image
Helus Pharma Expresses Support for Executive Order Advancing Psychedelic Research and Regulatory Pathways for Serious Mental Health Conditions
From Helus Pharma
Via GlobeNewswire
News headline image
Helus Pharma Announces Chief Executive Officer Transition; Eric So to Resume Role as Interim Chief Executive Officer
From Helus Pharma
Via GlobeNewswire
TinyGemsBreaks – Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) Appoints Dr. Ken Kramer SVP Medical Affairs
Via Investor Brand Network
News headline image
Helus Pharma Strengthens Medical Leadership by Appointing Dr. Ken Kramer as Senior Vice President, Medical Affairs
From Helus Pharma
Via GlobeNewswire
PsychedelicNewsBreaks – Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) Appoints Jill Conwell as Chief People Officer
Via Investor Brand Network
News headline image
Helus Pharma Strengthens Executive Team with Appointment of Jill Conwell as Chief People Officer
From Helus Pharma
Via GlobeNewswire
BioMedNewsBreaks — Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) Reports Positive Phase 2 Results for HLP004 in Generalized Anxiety Disorder
Via Investor Brand Network
News headline image
Anxiety Treatment Boom: GAD Therapies Poised for Multi-Billion Dollar Expansion
EQNX::TICKER_START (NNASDAQ:HELP),(CBOE:HELP),(NASDAQ:ACHC),(NYSE:JNJ),(NASDAQ:BWAY),(NASDAQ:AIFF) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
Helus Pharma Announces Topline Results in Phase 2 Signal Detection Study for HLP004 in Patients with Generalized Anxiety Disorder
From Helus Pharma
Via GlobeNewswire
TinyGemsBreaks – Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) Appoints Dr. Freda Lewis-Hall to Board and Scientific Advisory Committee Chair
Via Investor Brand Network
News headline image
Next-Generation Psychiatric Therapies Target Massive $40B+ Market Opportunity
EQNX::TICKER_START (NASDAQ:HELP),(CBOE:HELP),(NYSE:TAK),(NASDAQ:CMPS),(NYSE:PFE),(NYSE:BMY) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
Helus Pharma Appoints Former Pfizer Chief Medical Officer Dr. Freda Lewis-Hall to Board of Directors & Chair of the Scientific Advisory Committee
In this role, Dr. Lewis-Hall will guide clinical development strategy, regulatory engagement, and translational rigor across Helus’ novel serotonergic agonist (“NSA”) portfolio This news release... 
Via FinancialNewsMedia
News headline image
Helus Pharma Appoints Former Pfizer Chief Medical Officer Dr. Freda Lewis-Hall to Board of Directors & Chair of the Scientific Advisory Committee
From Helus Pharma
Via GlobeNewswire
PsychedelicNewsBreaks – Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) Reports Positive Phase 2a SPL026 Data Published in Nature Medicine
Via Investor Brand Network
News headline image
Nature Medicine Publishes Helus Pharma’s Randomized, Placebo-Controlled Phase 2a Trial of SPL026 in Major Depressive Disorder
From Helus Pharma
Via GlobeNewswire
BioMedNewsBreaks — Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) Reports Q3 2025 Results, Advances Phase 3 and Phase 2 Programs
Via Investor Brand Network
Topics Intellectual Property
News headline image
HELUS Pharma Reports Third Quarter Fiscal Year 2026 Financial Results and Recent Business Highlights
From Helus Pharma
Via GlobeNewswire
BioMedNewsBreaks — Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) Appoints Michael Cola as Chief Executive Officer
Via Investor Brand Network
Topics Intellectual Property
News headline image
Novel Serotonergic Agonists Positioned to Capture Share of $150B+ Neuropsychiatric Market
EQNX::TICKER_START (NASDAQ:HELP),(NYSE:JNJ),(NYSE:ABBV),(NYSE:TAK),(NYSE:AZN) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
Helus Pharma Appoints Michael Cola as Chief Executive Officer to Lead Next Phase of Scale and Execution
Former President of Shire PLC’s (“Shire”) Specialty Pharmaceutical business, with more than 30 years of experience across neuroscience, rare disease, and specialty pharmaceuticals, including senior... 
Via FinancialNewsMedia
Topics Intellectual Property
News headline image
Helus Pharma Appoints Michael Cola as Chief Executive Officer to Lead Next Phase of Scale and Execution
From Helus Pharma
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.